Evidence Digest - Archive
- 24 Jun 2022 - Paxlovid and hospitalisations, continuing COVID-19 waves, risk of long COVID with Delta and Omicron, mRNA vaccines for under-5s. (PDF 169 KB)
- 17 Jun 2022 - Telerehabilitation post-discharge, effects of previous infection & vaccination on Omicron infection, research questions on long COVID. (PDF 197 KB)
- 10 Jun 2022 - Long term physical and mental sequelae of COVID-19, tixagevimab–cilgavimab for prevention, natural and hybrid immunity to SARS-CoV-2. (PDF 196 KB)
- 3 Jun 2022 - COVID-19 in pregnancy, adapting vaccines in the changing face of SARS-CoV-2, Evusheld for preventing COVID-19 during Omicron. (PDF 168 KB)
- 27 May 2022 - COVID-19 sequelae and immunity, long COVID, Omicron BA.4 and BA.5, variant specific symptoms. (PDF 187 KB)
- 23 May 2022 - Long COVID symptoms after COVID-19 vaccination, immune escape by Omicron variants, reinfections. (PDF 163 KB)
- 20 May 2022 - Phase 3 trial of Comirnaty (Pfizer) third dose, unexplained post-acute infection syndromes, first COVID-19 Breathalyzer. (PDF 160 KB)
- 19 May 2022 - Immune response in COVID-19, changes in smell and taste perception, the role of community leaders during the pandemic in Australia. (PDF 158 KB)
- 18 May 2022 - Intracellular overdrive for SARS-CoV-2, T cell defence against COVID-19, generating evidence during a pandemic (PDF 162 KB)
- 17 May 2022 - Prone positioning and endotracheal intubation, impact of leadership on the nursing workforce, prevalence of post-intensive care syndrome. (PDF 194 KB)
- 16 May 2022 - Human-to-dog SARS-CoV-2 transmission, COVID-19 pre-symptomatic detection using a smartwatch, zero COVID strategy in China. (PDF 158 KB)
- 13 May 2022 - Spikevax (Moderna) in children aged 6 to 11 years, two-year health outcomes in hospitalised COVID-19 patients, coronavirus ‘ghosts’. (PDF 160 KB)
- 12 May 2022 - Effectiveness of COVID-19 vaccination in pregnancy, COVID-19 mutation in an immunocompromised host, fulminant onset COVID-19. (PDF 157 KB)
- 11 May 2022 - Mortality among patients with cancer and SARS-CoV-2, fourth-dose mRNA vaccine boosters, efficacy of monoclonal antibodies against Omicron. (PDF 159 KB)
- 10 May 2022 - Psychotropic medications and risk of COVID-19, tackling endoscopy backlogs due to COVID, UK updates on variants and long COVID. (PDF 164 KB)
- 9 May 2022 - Built environment and aerosol contamination, third dose vaccines vs Delta and Omicron, sensitivity of omicron subvariants to monoclonal antibodies. (PDF 151 KB)
- 6 May 2022 - New COVID-19 vaccines, convalescent plasma for early outpatient treatment, ECMO for acute COVID-19 respiratory failure. (PDF 154 KB)
- 5 May 2022 - Remdesivir for hospitalised COVID-19 patients, Omicron BA.4 and BA.5 lineages, BA.2.12.1 (PDF 154 KB)
- 4 May 2022 - Human genetic epidemiology of COVID-19, pathophysiology of COVID-19 ARDS and MIS-C in children, mRNA vaccine effectiveness over time. (PDF 183 KB)
- 3 May 2022 - Home antigen testing over the course of SARS-CoV-2 infection, impact of the pandemic on general practice in Australia, Omicron BA.4 and BA.5. (PDF 166 KB)
- 2 May 2022 - Household secondary SARS-CoV-2 attack rates, glycaemic control and breakthrough infections, smart lockdowns to control COVID-19. (PDF 156 KB)
- 29 Apr 2022 - Online breathing and wellbeing program for persistent COVID symptoms, symptom burden questionnaire for long COVID, parosmia practice points. (PDF 154 KB)
- 28 Apr 2022 - COVID-19 in pregnancy, digital health innovations for non-communicable disease management, online misinformation and vaccine hesitancy. (PDF 153 KB)
- 27 Apr 2022 - Infection induced and vaccine-induced immunity, second booster in adults aged 60+ years, chilblains and COVID-19 diagnoses in Victoria. (PDF 194 KB)
- 26 Apr 2022 - Evusheld for COVID-19 prevention, awake prone positioning, outcomes associated with non-invasive ventilation, high-flow oxygen and CPAP. (PDF 206 KB)
- 19 Apr 2022 - COVID-19 and kidney disease, fourth dose of Pfizer, protection following booster in adolescents, changes in life expectancy between 2019 & 2020. (PDF 189 KB)
- 14 Apr 2022 - COVID-19 vaccines in solid organ transplant recipients, oral famotidine, estimating disease severity of Omicron and Delta infections. (PDF 159 KB)
- 13 Apr 2022 - Myopericarditis after vaccination, long COVID occurrence, BA.1 and BA.2 immune response in naïve and prior infected persons. (PDF 162 KB)
- 12 Apr 2022 - Global, regional and national daily and cumulative SARS-CoV-2 infections, COVID-19 vaccine waning and the effectiveness of boosters, BA.4 and BA.5 (PDF 171 KB)
- 11 Apr 2022 - Budenoside, differences between Omicron and Delta infections, thromboembolism and bleeding after COVID-19. (PDF 160 KB)
- 8 Apr 2022 - Fluvoxamine for outpatients, COVID-19 and stroke treatment response times, sotrovimab resistance in immunocompromised COVID-19 patients. (PDF 195 KB)
- 7 Apr 2022 - Fourth dose of Comirnaty (Pfizer) against Omicron, the course of Long COVID, dynamics and scale of the Omicron epidemic in England. (PDF 163 KB)
- 6 Apr 2022 - COVID-19 and risk factors in cancer patients, cardiac impairment in Long COVID, Omicron infections in triple vaccinated individuals. (PDF 161 KB)
- 5 Apr 2022 - The COVID Positive Pathway in Melbourne, non-pharmacological interventions, preparing for the next COVID-19 viral variant. (PDF 164 KB)
- 4 Apr 2022 - Phase 3 trial of a DNA vaccine, risk of reinfection and hospitalisation with natural and hybrid immunity, human challenge trial, influenza under COVID. (PDF 167 KB)
- 1 Apr 2022 - Early ivermectin treatment, ruxolitinib, SARS-CoV-2 pathogenesis, Pfizer vaccine protection against Omicron in children and adolescents. (PDF 160 KB)
- 31 Mar 2022 - SARS-CoV-2 reinfections in children, hydration of the nose, larynx, and trachea to reduce COVID-19 symptoms, a global epidemiological database. (PDF 162 KB)
- 30 Mar 2022 - TMPRSS2 inhibitor, global genomic surveillance, corticosteroid monotherapy in multisystem inflammatory syndrome in children. (PDF 160 KB)
- 29 Mar 2022 - Parenchymal lung abnormalities, tocilizumab plus dexamethasone vs dexamethasone, SARS-CoV-2 entry into cells, vaccine vs Omicron BA.2. (PDF 198 KB)
- 28 Mar 2022 - Awake prone positioning, COVID-19 vaccination in pregnancy, early aspirin use and mortality, ATAGI recommendations for second booster. (PDF 162 KB)
- 25 Mar 2022 - The safety and efficacy of a third does of Comirnaty (Pfizer), incident diabetes in long COVID, viral load dynamics of Delta and Omicron. (PDF 166 KB)
- 24 Mar 2022 - Antiplatelet therapy, perinatal complications associated with SARS-CoV-2 infection during pregnancy, COVID-19 pneumonitis in children. (PDF 155 KB)
- 23 Mar 2022 - Comirnaty and Vaxzevria in people over 50, anticoagulation in patients with atrial fibrillation and COVID-19, surveillance systems for the new normal. (PDF 154 KB)
- 22 Mar 2022 - Active immunotherapy in cancer patients with COVID-19, socio-economic factors and incidence, two doses of Comirnaty (Pfizer) in 5-15 year olds. (PDF 198 KB)
- 21 Mar 2022 - SARS-CoV-2 transmission from mother-to-child, COVID-19 and cardiovascular disease, hospitalisation and death with Omicron and Delta. (PDF 172 KB)
- 18 Mar 2022 - High-flow oxygen therapy and non-invasive ventilation, losartan treatment for inpatients, neutralisation of Omicron BA.1 and BA.2 variants. (PDF 155 KB)
- 17 Mar 2022 - Molnupiravir, mechanical thrombectomy for acute ischaemic stroke in COVID-19 patients, acute COVID-19 severity and mental health trajectories. (PDF 170 KB)
- 16 Mar 2022 - Frailty and mortality risk, pausing methotrexate in older patients with rheumatic disease, antigenic evolution of SARS-CoV-2. (PDF 162 KB)
- 15 Mar 2022 - Excess mortality due to COVID-19, pulmonary rehabilitation for post-COVID-19, long COVID in children and adolescents. (PDF 164 KB)
- 14 Mar 2022 - Rapid and laboratory-free COVID-19 triage for emergency care, long COVID symptoms, Omicron stability on various surfaces. (PDF 166 KB)
- 11 Mar 2022 - Seroconversion in mild COVID-19, resistance in Delta variant following sotrovimab use, recombinant Deltamicron, antivirals vs Omicron BA.2 (PDF 160 KB)
- 10 Mar 2022 - Dexamethasone post-discharge, cognitive changes in older COVID-19 survivors, self-collected gargle specimen for COVID-19 diagnosis. (PDF 162 KB)
- 9 Mar 2022 - Tocilizumab, SARS-CoV-2 and changes in brain structure, long COVID evaluation, secondary attack rates of Omicron and Delta in Norway. (PDF 163 KB)
- 8 Mar 2022 - Waning of viral load reduction post COVID-19 booster, Omicron BA.1 and BA.2 subvariants, co-infection with multiple variants. (PDF 162 KB)
- 7 Mar 2022 - Vaccines in immunocompromised patients, one-year outcomes post-pneumonia, processes and outcomes in dedicated COVID-19 hospitals. (PDF 160 KB)
- 4 Mar 2022 - Vaccine effectiveness against Omicron, wearable devices that detect COVID-19, the US COVID-19 preparedness plan. (PDF 160 KB)
- 3 Mar 2022 - Remdesivir for COVID-19 adults, COVID-19 infection in adults with intellectual disabilities, prescribing nirmatrelvir–ritonavir (PAXLOVID) (PDF 173 KB)
- 2 Mar 2022 - Prenatal and neonatal complications of COVID-19, ambulatory monitoring of COVID-19 patients, anticipating the next variant. (PDF 159 KB)
- 1 Mar 2022 - COVID-19 infection-fatality ratios, COVID-19 and rheumatic disease, waning effectiveness of vaccine third dose, TGA approval for EVUSHIELD. (PDF 167 KB)
- 28 Feb 2022 - Music therapy for hospitalised COVID-19 patients, sudden sensorineural hearing loss after COVID-19 vaccination, RATs for detecting infectiousness. (PDF 159 KB)
- 25 Feb 2022 - Treatment for COVID-19 or MIS-C in children, implementing digital health for global health security, ATAGI guide on Spikevax (Moderna) for children. (PDF 164 KB)
- 24 Feb 2022 - Duration of vaccine effectiveness, low-dose radiation therapy, frailty and COVID-19, cholecalciferol (vitamin D3) treatment. (PDF 163 KB)
- 23 Feb 2022 - Second allergic reaction to COVID-19 vaccines, mortality in cancer patients infected with COVID-19, severity of paediatric hospitalisations in the US. (PDF 152 KB)
- 22 Feb 2022 - Ivermectin treatment, paediatric hospitalisations and Omicron, risk of SARS-CoV-2 reinfection. (PDF 164 KB)
- 21 Feb 2022 - Risks of mental health outcomes post-COVID-19, identifying patients at risk of clinical deterioration, TGA approval for SPIKEVAX in people 6+ years old. (PDF 161 KB)
- 18 Feb 2022 - Oral nirmatrelvir, Comirnaty (Pfizer) effectiveness after COVID-19 recovery, childhood obesity and the risk of SARS-CoV-2 infection. (PDF 166 KB)
- 17 Feb 2022 - Geriatric risk factors for COVID-19 in adults with cancer, lessons from lived experience of long COVID, co-infection with Omicron and Delta variants. (PDF 160 KB)
- 16 Feb 2022 - SARS-CoV-2 infection and vaccination in rheumatic and musculoskeletal disease, Australia’s genomics surveillance platform (AusTrakka) (PDF 161 KB)
- 15 Feb 2022 - Casirivimab, imdevimab and favipiravir, ATAGI guidance, Omicron sublineages (PDF 169 KB)
- 14 Feb 2022 - Molnupiravir phase 3 trial, oral famotidine, Novavax clinical trial, future pandemic preparedness, antibody evasion of Omicron sublineages (PDF 169 KB)
- 11 Feb 2022 - Sofosbuvir-based treatment, neutralisation against Omicron from previous non-Omicron infection, long COVID in in adolescents (PDF 165 KB)
- 10 Feb 2022 - Long COVID-19 in children, outbreak preparedness in Australian aged care facilities, protection of vaccination and infection against Omicron and Delta (PDF 165 KB)
- 9 Feb 2022 - Oral antivirals, maternal outcomes, cardiovascular outcomes, antibodies 16 months post-infection, COVID-19 responses in OECD countries (PDF 190 KB)
- 8 Feb 2022 - ICU-specific virtual reality aftercare, post-peak dynamics in Omicron wave, TGA provisional determination for VEKLURY (remdesivir) (PDF 169 KB)
- 7 Feb 2022 - Azithromycin, mRNA vaccines in pregnancy, fact checking and the ‘infodemic’ (PDF 165 KB)
- 4 Feb 2022 - Antiviral therapies, bromhexine hydrochloride prophylaxis, pandemic preparedness in 177 countries, SARS-CoV-2 human challenge study. (PDF 156 KB)
- 3 Feb 2022 - Quadrivalent influenza vaccine administered with Spikevax, innate immunity vs SARS-CoV-2, immunology of SAR-CoV-2 infection in children. (PDF 179 KB)
- 2 Feb 2022 - Consumer interpretation of COVID-19 self-test kits, Omicron BA.1 & BA.2 in household transmission, building an evidence ecosystem (PDF 188 KB)
- 1 Feb 2022 - Tocilizumab and corticosteroids, memory B cells after triple vaccination, readmissions and deaths post COVID-19 hospitalisation (PDF 168 KB)
- 31 Jan 2022 - Remdesivir for outpatients, duration of protection by COVID-19 vaccines, relative infectiousness of breakthrough infections and reinfections (PDF 169 KB)
- 28 Jan 2022 - Reinfection risk after SARS-CoV-2, potential indirect impacts of COVID-19 on Australian children, immunoglobulin predictor of post-acute COVID-19 (PDF 218 KB)
- 27 Jan 2022 - Non-invasive respiratory strategies in COVID-19, high-dose polyclonal intravenous immunoglobulin, curcumin in treating COVID-19 (PDF 159 KB)
- 25 Jan 2022 - Boosters post-CoronaVac, immunotherapy, physicians seeking outpatient care for mental health and substance use during COVID-19 (PDF 167 KB)
- 24 Jan 2022 - Neutralising antibodies following CoronaVac and Comirnaty (Pfizer), clinical severity of Omicron, post-acute COVID-19 (long COVID) in Europe (PDF 157 KB)
- 21 Jan 2022 - Rapid COVID tests, Omicron and therapeutic monoclonal antibodies, breakthrough infections, Omicron symptoms (PDF 167 KB)
- 20 Jan 2022 - Melatonin, P2Y12 inhibitors in non-critical patients, COVID and pregnancy outcomes, mental health service for Australian healthcare workers (PDF 166 KB)
- 19 Jan 2022 - Healthcare use by children post-COVID, post-acute neurological consequences of COVID-19, T-cell responses to Omicron (PDF 158 KB)
- 18 Jan 2022 - Casirivimab and imdevimab, Comirnaty (Pfizer) booster effectiveness, COVID-19 therapeutics for non-hospitalised patients (PDF 163 KB)
- 17 Jan 2022 - COVID-19 in adolescents, indirect impacts of COVID-19 on childhood infections, clinical outcomes in the Omicron wave (PDF 170 KB)
- 11 Jan 2022 - Atorvastatin, false-positive RATs, heterologous boosters, TGA provisional determination for EVUSHELD (PDF 172 KB)
- 4 Jan 2022 - Reducing self-isolation periods, Omicron breakthrough infections, hospitalisations and vaccine protection (PDF 174 KB)
- 24 Dec 2021 - Molnupiravir, remdesivir, booster protection, neutralisation and severity of Omicron (PDF 171 KB)
- 17 Dec 2021 - Hyperbaric oxygen treatment, Novavax phase 3 trial, the need for updated evidence synthesis, universal COVID-19 vaccines (PDF 167 KB)
- 16 Dec 2021 - Asymptomatic SARS-CoV-2 infections, sarilumab, COVID-19 in 2022, boosters and Omicron (PDF 158 KB)
- 15 Dec 2021 - High vs standard intensity of thromboprophylaxis, COVID-19 convalescent plasma, reinfections in Australia, pulse oximetry for home monitoring (PDF 188 KB)
- 14 Dec 2021 - COVID-19 and anti-TNF treatments, droplet digital PCR, breakthrough infections with Omicron variant despite mRNA booster (PDF 163 KB)
- 13 Dec 2021 - Volatile organic compounds-based breath analysis, PPE litter, public health system requirements in Australia (PDF 158 KB)
- 10 Dec 2021 - Comirnaty (Pfizer) vaccine booster, post-acute COVID-19, Omicron studies, TGA approval for Spikevax (Moderna) booster. (PDF 162 KB)
- 9 Dec 2021 - Protection from natural immunity vs vaccination, heterologous vaccination, global response to Omicron, breakthrough infections, Omicron and Pfizer. (PDF 165 KB)
- 8 Dec 2021 - Anticoagulant regimens, care of older people and people requiring palliative care with COVID-19, healthcare access for young Australians. (PDF 183 KB)
- 7 Dec 2021 - Randomised controlled trial of seven COVID-19 vaccines as boosters, breakthrough infections, spike proteins on the Omicron and Delta variants (PDF 164 KB)
- 6 Dec 2021 - Treatment studies, BMJ series on China’s response to COVID-19, transmission routes, Omicron and reinfection (PDF 174 KB)
- 3 Dec 2021 - Baricitinib, predictive scores for pulmonary embolism, asthma and COVID-19 in children, persistent pulmonary pathology (PDF 184 KB)
- 2 Dec 2021 - Universal COVID-19 testing in Hong Kong, booster vaccination effectiveness, pulse oximetry remote monitoring (PDF 138 KB)
- 1 Dec 2021 - Immunomodulation and thromboembolic risk, BMJ series on COVID-19 preparedness, response and future implications, COVID trends in children (PDF 161 KB)
- 30 Nov 2021 - Prevention strategy, fungal infections, WHO updates on Omicron (PDF 179 KB)
- 29 Nov 2021 - Sustainable futures after COVID-19, effectiveness of Comirnaty and Vaxzevria against household transmission, Omicron variant of concern (PDF 192 KB)
- 26 Nov 2021 - Non-pharmaceutical inventions, ‘positive expiratory pressure flute self-care’ in early COVID-19, rapid antigen tests (PDF 165 KB)
- 25 Nov 2021 - Subcutaneous interferon-beta, neurological complications of COVID-19, TGA approval for RONAPREVE (casirivimab + imdevimab) (PDF 166 KB)
- 24 Nov 2021 - Umifenovir, inhaled ciclesonide for outpatient treatment, long-term sequelae one year after COVID-19 hospitalisation (PDF 193 KB)
- 23 Nov 2021 - Novavax co-administered with influenza vaccines, antibody titres before and after mRNA boosters, care models for post-acute COVID-19 syndrome (PDF 165 KB)
- 22 Nov 2021 - Public health measures for COVID-19, aspirin in hospitalised COVID-19 patients, leadership development (PDF 156 KB)
- 19 Nov 2021 - Mental health concerns during COVID-19, factors associated with waning immunity, booster dose effectiveness (PDF 158 KB)
- 18 Nov 2021 - Neutralising antibody titres, lopinavir-ritonavir prophylaxis, automated text messaging service for monitoring COVID-19 at home (PDF 159 KB)
- 17 Nov 2021 - SARS-CoV-2 antigen tests, COVID-19 treatment for pregnant women, entering Australia’s third year with COVID-19 (PDF 195 KB)
- 16 Nov 2021 - Covaxin (BBV152) vaccine, intravenous immunoglobulins, burden of post-acute sequelae of COVID-19 (PDF 169 KB)
- 15 Nov 2021 - Immunomodulators for COVID-19, deaths in children after SARS-CoV-2 infection in England, the future of SARS-CoV-2 vaccination (PDF 159 KB)
- 12 Nov 2021 - Comirnaty (Pfizer) vaccine for children, Spikevax (Moderna) in cancer patients receiving treatment, aerosol generating procedures (PDF 155 KB)
- 11 Nov 2021 - Crucial junctures in the pandemic, the impact of government interventions on COVID-19 transmission, waning immunity (PDF 155 KB)
- 10 Nov 2021 - Molnupiravir, paxlovid, continuous remote monitoring of COVID-19 patients, key epidemiological parameters of COVID-19 (PDF 154 KB)
- 9 Nov 2021 - COVID-19 rapid diagnostics, aerosol generation from oxygen delivery systems, face mask leakage and facial features, paediatric vaccines (PDF 159 KB)
- 8 Nov 2021 - COVID-19 in Victoria, COVID-19 sequelae in cancer patient survivors, breakthrough infections (PDF 164 KB)
- 5 Nov 2021 - COVID-19 vaccination in children, immune responses of neonates, elimination vs mitigation strategies (PDF 154 KB)
- 4 Nov 2021 - Vaccine side effects, ciclesonide for outpatients, COVID-19 in newborns, portable air purifiers to reduce airborne transmission (PDF 163 KB)
- 3 Nov 2021 - Tocilizumab, vitamin D and COVID-19, bamlanivimab and etesevimab, Victoria’s second wave (PDF 193 KB)
- 2 Nov 2021 - Vaccine boosters, COVID-19-related death in vaccinated people, severe SARS-CoV-2 infection in children (PDF 163 KB)
- 1 Nov 2021 - Vaccine- and infection-induced immunity, delta community transmission among vaccinated and unvaccinated people, vaccines for under 12s (PDF 179 KB)
- 29 Oct 2021 - Sotrovimab, naproxen, waning immunity after vaccination with Comirnaty (Pfizer), the effect of vaccination on transmission (PDF 167 KB)
- 28 Oct 2021 - COVID-19 vaccines and children, mesenchymal stem cell treatment, TGA approval for Comirnaty (Pfizer) booster (PDF 154 KB)
- 27 Oct 2021 - Interferon-β, sensitivity of SARS-CoV-2 rapid antigen tests, the clinical care of children and adolescents with COVID-19 (PDF 223 KB)
- 26 Oct 2021 - Waning immunity and booster strategies, rapid antigen tests, SARS-CoV-2 infection in school-aged children (PDF 166 KB)
- 25 Oct 2021 - Dexamethasone dosage, heterologous vaccination with Vaxzevria and Comirnaty, climatic signatures in COVID-19 waves (PDF 159 KB)
- 22 Oct 2021 - Untested infectious individuals in the spread of COVID-19, toxic effects from ivermectin use, WHO public health checklists for aviation and ports (PDF 145 KB)
- 21 Oct 2021 - Colchicine, acute respiratory distress syndrome and corticosteroids, sarilumab for COVID-19 pneumonia, COVID-19 infodemic management (PDF 156 KB)
- 20 Oct 2021 - COVID-19 vaccines against Delta, a post-exposure nasal spray, methods for short term forecasts of COVID-19 admissions (PDF 192 KB)
- 19 Oct 2021 - Glucocorticoids and viral clearance, haemoperfusion and blood purification strategies, reopening of international borders in Australia (PDF 198 KB)
- 18 Oct 2021 - Anakinra, screening in asymptomatic individuals, effect of vaccination on symptoms of post-acute COVID-19 syndrome (PDF 158 KB)
- 15 Oct 2021 - COVID-19 blockchain applications, post-acute sequelae of COVID-19, respiratory sub-phenotypes in COVID-19 patients with ARDS (PDF 155 KB)
- 14 Oct 2021 - Ruxolitinib, transmission in primary schools, heightened prenatal anxiety and depression during lockdown (PDF 158 KB)
- 13 Oct 2021 - Digital contact tracing, effect of mandatory COVID-19 certificates on vaccine uptake, WHO international travel public health measures (PDF 144 KB)
- 12 Oct 2021 - COVID-19 depressive and anxiety disorders, cannabidiol, mortality in people with mental disorders and intellectual disabilities during COVID-19 (PDF 163 KB)
- 11 Oct 2021 - Immunomodulatory therapies in COVID-19, antiviral mouthwash, boosters, COVID-19 in children infected with the Delta variant (PDF 168 KB)
- 8 Oct 2021 - Bamlanivimab and etesevimab, maternal SARS-CoV-2 infection, waning of Comirnaty (Pfizer) vaccine protection, WHO guide on antigen tests. (PDF 163 KB)
- 7 Oct 2021 - Tocilizumab, hospital prevalence as a mortality risk factor, antiplatelet therapy, WHO statement on booster doses (PDF 167 KB)
- 6 Oct 2021 - Antidiabetic agents and mortality risk, durability of immunity against reinfection, navigating from SARS-CoV-2 elimination to endemicity (PDF 175 KB)
- 5 Oct 2021 - Ventilator-associated pneumonia, behavioural interventions for physical distancing, vaccination and post-acute sequelae of COVID-19 (PDF 183 KB)
- 1 Oct 2021 - Post-acute COVID-19 syndrome, pharmacological interventions, extracorporeal membrane oxygenation (ECMO) for COVID-19 (PDF 165 KB)
- 30 Sep 2021 - Statins and COVID-19, news media coverage of public health and policy messages, serum magnesium levels in COVID-19 (PDF 164 KB)
- 29 Sep 2021 - Tocilizumab, consent for vaccination for children, transmission of Delta in a partially vaccinated population, TGA news on self-tests (PDF 153 KB)
- 28 Sep 2021 - Antibody and cellular therapies in treating COVID-19, visual summary of guidelines for COVID-19 treatment, mRNA vaccines (PDF 161 KB)
- 27 Sep 2021 - Venous thromboembolism and severe COVID-19, waning immunity post-vaccination, mental health professionals encouraging vaccination (PDF 152 KB)
- 24 Sep 2021 - Multisystem inflammatory syndrome in adults, phase 3 trials of Spikevaxand, REGEN-COV antibody combination to prevent COVID-19 (PDF 170 KB)
- 23 Sep 2021 - Heparin, corticosteroids, favipiravir and arbidol, lung ultrasound for diagnosis (PDF 164 KB)
- 22 Sep 2021 - Saliva testing in primary care and for children, antivirals for COVID-19 (PDF 185 KB)
- 21 Sep 2021 - ROX index as a predictor of high flow nasal cannula failure, risk prediction of COVID-19 related death and hospitalisation after vaccination (PDF 155 KB)
- 20 Sep 2021 - L-arginine treatment, menstrual changes after COVID-19 vaccination, considerations for booster vaccination (PDF 191 KB)
- 17 Sep 2021 - Prophylactic anticoagulation regimens, variant-modified mRNA vaccine boosters, resistance mutations to monoclonal antibodies (PDF 162 KB)
- 16 Sep 2021 - COVID-19 and the ageing immune system, self-sanitising masks, effectiveness and protection period of Pfizer, AstraZeneca and Moderna (PDF 161 KB)
- 15 Sep 2021 - Extended use of N95 masks, COVID-19 quarantine system failures, policy considerations for mandatory COVID-19 vaccination (PDF 165 KB)
- 14 Sep 2021 - Telecare case management, rapid antigen testing in children, the need for non-pharmaceutical interventions in long term care post-vaccination (PDF 156 KB)
- 13 Sep 2021 - High-intensity interval training after COVID-19 hospitalisation, impact of lockdown on key workers, vaccine passport (PDF 154 KB)
- 10 Sep 2021 - Mental and neurological disorders and COVID-19 risk, dynamics of antibody responses to Pfizer, COVID-19 lessons for pharmacists (PDF 144 KB)
- 9 Sep 2021 - Readmitted COVID-19 survivors, Pfizer in pregnancy, learning to live with COVID-19 in Australia (PDF 154 KB)
- 8 Sep 2021 - Late second dose or booster of AstraZeneca, baricitinib treatment, trends in emergency admissions for diabetic ketoacidosis (PDF 167 KB)
- 7 Sep 2021 - SARS-CoV-2 vaccination in immune-mediated inflammatory diseases, anakinra for early treatment, anti-SARS-CoV-2 seroprevalence in the US (PDF 170 KB)
- 6 Sep 2021 - Allergic reactions after Pfizer vaccination, casirivimab-imdevimab treatment, post vaccination SARS-CoV-2 infections (PDF 153 KB)
- 3 Sep 2021 - COVID-19 and immune-mediated inflammatory diseases, resurgence of SARS-CoV-2 infection in vaccinated healthcare workforce (PDF 151 KB)
- 2 Sep 2021 - Risk-factors for hospital readmission, Pfizer boosters, projected resurgence of COVID-19 in the US (PDF 119 KB)
- 1 Sep 2021 - Thrombocytopaenia and thromboembolism after vaccination, COVID-19 risk by occupation in healthcare workers (PDF 142 KB)
- 31 Aug 2021 - Household transmission, door-to-door COVID-19 testing program, one year outcomes post-hospitalisation for COVID-19, waning immunity (PDF 156 KB)
- 30 Aug 2021 - Hospitalisations and the Delta variant, vaccine effectiveness against Delta, TGA approval of Pfizer for 12+ years (PDF 158 KB)
- 27 Aug 2021 - Therapeutic anticoagulation with heparin, protecting long-term care facilities from COVID-19, negative seroconversion (PDF 151 KB)
- 26 Aug 2021 - Anticoagulation treatment, mental health and wellbeing of children and adolescents, emergency department design during COVID-19 (PDF 154 KB)
- 25 Aug 2021 - COVID-19 transmission dynamics, SARS-CoV-2 reinfection, Delta variant transmission in schools (PDF 150 KB)
- 24 Aug 2021 - Hyperbaric oxygen therapy, real-world effectiveness of COVID-19 vaccines, TGA approval for sotrovimab (PDF 145 KB)
- 23 Aug 2021 - Sensitivity and specificity of rapid antigen tests, use of mobility data in local containment, COVID-19 and social relationships and health (PDF 154 KB)
- 20 Aug 2021 - School closures and COVID-19 transmission, convalescent plasma for high-risk outpatients, advance care planning during COVID-19 (PDF 156 KB)
- 19 Aug 2021 - Insulin treatment and COVID-19, long-term sequelae of COVID-19 in people with airways disease, rapid antigen tests in nursing homes. (PDF 134 KB)
- 18 Aug 2021 - Evidence base of COVID-19 guidelines, outcomes of breakthrough infections, COVID-19 in Australian children (PDF 166 KB)
- 17 Aug 2021 - Novel antigen rapid diagnostics for SARS-CoV-2, cannabidiol therapy for healthcare workers, remote patient monitoring (PDF 141 KB)
- 16 Aug 2021 - COVID-19 mortality in Europe, AstraZeneca and Pfizer homologous and heterologous immunisation, surgical leadership during COVID-19 (PDF 142 KB)
- 13 Aug 2021 - Convalescent plasma, budesonide for COVID-19 in people at high risk, Moderna vaccine for adolescents (PDF 162 KB)
- 12 Aug 2021 - Electroconvulsive therapy, COVID-19 prevention and control measures in workplace settings, antigen testing (PDF 149 KB)
- 11 Aug 2021 - Long-term effects of COVID-19, anakinra, vaccines versus the Delta variant, TGA approval of Moderna vaccine (PDF 139 KB)
- 10 Aug 2021 - Pulmonary embolism in COVID-19 patients, BTK inhibitors, rapid antigen testing. (PDF 165 KB)
- 9 Aug 2021 - Steroids for non-oxygen requiring patients, mandatory vaccinations for healthcare workers, breakthrough infections (PDF 151 KB)
- 6 Aug 2021 - Janus kinase inhibitors, therapeutic anticoagulation with heparin, monoclonal antibodies REGEN-COV for COVID-19 prevention (PDF 153 KB)
- 5 Aug 2021 - Isolation measures and people with dementia, convalescent plasma, global burden of acute myocardial injury associated with COVID-19 (PDF 135 KB)
- 4 Aug 2021 - Behavioural nudges to increase COVID-19 vaccination, mass vaccination and lockdown requirements, interpreting time series of COVID-19 data (PDF 140 KB)
- 3 Aug 2021 - The safety profile of COVID-19 vaccines, asymptomatic COVID-19 infection, mandating vaccination for healthcare workers in the US (PDF 147 KB)
- 2 Aug 2021 - SARS-CoV-2 viral particles in the retina, self- reported memory problems post COVID-19, reactive vaccination approaches to outbreaks (PDF 196 KB)
- 30 Jul 2021 - Mood disorders and risk of COVID-19, tofacitinib for COVID-19 pneumonia, identifying and tracking SARS-CoV-2 variants (PDF 142 KB)
- 29 Jul 2021 - Predicting clinical deterioration, mental health disorders and mortality, rapid antigen tests, leadership of healthcare teams beyond COVID-19. (PDF 140 KB)
- 28 Jul 2021 - Telerehabilitation for COVID-19 patients, post-acute COVID-19 syndrome, daily testing of schoolchildren (PDF 139 KB)
- 27 Jul 2021 - Enoxaparin in severe COVID-19, high-dose parenteral vitamin D3, improving healthcare delivery, reinfections. (PDF 148 KB)
- 26 Jul 2021 - Temperature screening in COVID-19 triage, extended dosing of Pfizer vaccine, updated ATAGI advice (PDF 185 KB)
- 23 Jul 2021 - Dapagliflozin in patients with cardiometabolic risk factors, effectiveness of COVID-19 vaccines against the Delta variant. (PDF 158 KB)
- 22 Jul 2021 - Solar UV-B/A radiation in inactivating SARS-CoV-2, viral infectivity 27 days after onset of COVID-19 symptoms, WHO weekly updates. (PDF 134 KB)
- 21 Jul 2021 - COVID-19 vaccines, tocilizumab and systemic corticosteroids, frequency and phenotype of headache in COVID-19 patients (PDF 142 KB)
- 20 Jul 2021 - In-hospital COVID-19 complications, high-risk groups for severe COVID-19 in NSW, outcomes in vaccinated patients hospitalised with Delta variant (PDF 142 KB)
- 19 Jul 2021 - COVID-19 and mental disorders, learning disability, increased virulence of variants (PDF 157 KB)
- 16 Jul 2021 - Phase 3 trial of monoclonal antibodies, physician-delivered messages for COVID-19 behaviours, vaccination plus non-pharmaceutical interventions. (PDF 145 KB)
- 15 Jul 2021 - SARS-CoV-2 antibodies in human milk, COVID-19 and people with spinal cord injury (PDF 173 KB)
- 14 Jul 2021 - Pfizer vaccine in pregnant women, mandating COVID-19 vaccines for healthcare workers, features of a Delta variant outbreak. (PDF 133 KB)
- 13 Jul 2021 - Vaccine hesitancy, aerosol transmission and medical procedures, vaccine passports and health disparities. (PDF 151 KB)
- 12 Jul 2021 - Phase 3 trial of CoronaVac, guidance for healthcare leaders, sensitivity of Delta variant to antibody neutralisation, COVID-19 endgame scenarios. (PDF 143 KB)
- 9 Jul 2021 - Variants and vaccines, telehealth in Australian cardiology, COVID-19 outcomes in Sydney, asymptomatic rapid testing. (PDF 143 KB)
- 8 Jul 2021 - WHO living guideline on therapeutics and COVID-19, IL-6 antagonists and mortality, biomarkers for asymptomatic infection (PDF 154 KB)
- 7 Jul 2021 - Meta-analysis of phase 3 trials of COVID-19 vaccines, caseload surge and COVID-19 survival, breakthrough infections (PDF 120 KB)
- 6 Jul 2021 - COVID-19 vaccine prioritisation, presymptomatic SARS-CoV-2 transmission, WHO guidance on international travel (PDF 202 KB)
- 5 Jul 2021 - Phase 3 trial of Novavax, age-related immune response to Pfizer vaccine, telenursing home care and COVID-19 (PDF 141 KB)
- 2 Jul 2021 - Phase 3 trial of Novavax, age-related immune response to Pfizer vaccine, telenursing home care and COVID-19 (PDF 161 KB)
- 1 Jul 2021 - Ivermectin treatment for COVID-19, reinfection and reactivation of SARSCoV-2, CoronaVac vaccine in children. (PDF 140 KB)
- 30 Jun 2021 - Parents’ consideration for child vaccination, extubation of ventilated COVID-19 patients, thrombosis after Moderna vaccination. (PDF 169 KB)
- 29 Jun 2021 - COVID-19 in family clusters, interventions to increase personal protective behaviours, Pfizer booster in AstraZeneca-primed participants. (PDF 148 KB)
- 28 Jun 2021 - Global seroprevalence of SARS-CoV-2 antibodies, Bell palsy, the impact of COVID-19 on life expectancy (PDF 160 KB)
- 25 Jun 2021 - Invasive mould disease in fatal COVID-19, variants and vaccines, genomic evolution of SARS-CoV-2 in an immunocompromised patient (PDF 153 KB)
- 24 Jun 2021 - Allergic reaction to SARS-CoV-2 vaccines, hospitalisation and the Alpha (B.1.1.7) variant, international comparison of containment strategies (PDF 150 KB)
- 23 Jun 2021 - Child mortality in England during COVID-19, persistent pulmonary disease, sustainable long-term infrastructure for COVID-19 vaccinations (PDF 142 KB)
- 22 Jun 2021 - Pneumothorax and COVID-19, AstraZeneca vaccine for people with HIV, transmissibility and global spead of SAR-CoV-2 variants (PDF 175 KB)
- 21 Jun 2021 - Mucormycosis, smoking and COVID-19 outcomes, ATAGI revised recommendations on AstraZeneca vaccine (PDF 140 KB)
- 18 Jun 2021 - Tofacitinib for COVID-19 pneumonia, control measures during vaccination rollout, COVID-19 systemic pathogenesis (PDF 141 KB)
- 17 Jun 2021 - Risk of hospital admission with Alpha (B.1.1.7) variant, nursing student acceptance of vaccination, the nursing profession post-COVID-19. (PDF 142 KB)
- 16 Jun 2021 - Saliva or nasopharyngeal swabs for SARS-CoV-2 screening, reninangiotensin-system inhibitors, social pharmacology (PDF 164 KB)
- 15 Jun 2021 - Obesity and COVID-19, repatriation in South Australia, managing vaccineinduced immune thrombosis and thrombocytopaenia in Australia (PDF 153 KB)
- 11 Jun 2021 - COVID-19 vaccine prioritisation, persistent SARS-CoV-2 infections, tracking SARS-CoV-2 variants. (PDF 168 KB)
- 10 Jun 2021 - Pregnancy and neonatal outcomes, ‘COVID-19 conscience tracing’, nanotraps to prevent SARS-CoV-2 from infecting cells (PDF 176 KB)
- 9 Jun 2021 - Neonates with COVID-19 positive mothers, underlying medical conditions associated with severe COVID-19 in children, mask-related acne. (PDF 145 KB)
- 8 Jun 2021 - Neurology and neuropsychiatry of COVID-19, ED presentations from Sydney quarantine hotels, COVID-19 swab-related skull injury (PDF 173 KB)
- 7 Jun 2021 - Efficacy of COVID-19 vaccines, SARS-CoV-2 detection dogs, ‘five Cs’ to tackle vaccine hesitancy (PDF 217 KB)
- 4 Jun 2021 - Co-infections and secondary infections, COVID-19 transmission in group living environments, an osteo-metabolic phenotype of COVID-19 (PDF 167 KB)
- 3 Jun 2021 - SARS-CoV-2 variants and immune escape, WHO announces new names for variants of concern and interest (PDF 139 KB)
- 2 Jun 2021 - Vaccination and rheumatic disease, adipokines and obesity and severe COVID-19, breakthrough infections (PDF 137 KB)
- 1 Jun 2021 - Vaccine breakthrough infections, reinfections, seropositivity in Pfizer vaccinated cancer patients (PDF 138 KB)
- 31 May 2021 - Tracheostomy and COVID-19, Pfizer vaccine in adolescents, ATAGI update (PDF 140 KB)
- 28 May 2021 - Persistent COVID-19 symptoms, phase 3 trials of two inactivated SARSCoV-2 vaccines, ocular findings in COVID-19 survivors (PDF 159 KB)
- 27 May 2021 - Corticosteroid therapy for COVID-19, infectiousness ‘through the infection course’, protecting Olympians from COVID-19 (PDF 167 KB)
- 26 May 2021 - Weather and COVID-19, 6-month post diagnosis of paediatric inflammatory multisystem syndrome, controls for air travel into COVID-19 free countries (PDF 159 KB)
- 25 May 2021 - Post-acute COVID-19 syndrome, mixed prime-boost vaccines, vaccine effectiveness against variant B.1.617.2 (India) (PDF 185 KB)
- 24 May 2021 - Vaccine hesitancy practice pointer, excess deaths in 29 high-income countries, post-acute COVID-19 (PDF 166 KB)
- 21 May 2021 - COVID-19 and liver abnormalities, prone positioning, PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia (PDF 163 KB)
- 20 May 2021 - COVID-19 reinfection, virtual primary care, data concerns about the Sputnik vaccine (PDF 143 KB)
- 19 May 2021 - COVID-19 BMJ Best Practice guide, cytokine adsorption in ECMO patients, communicating about vaccine safety (PDF 155 KB)
- 18 May 2021 - JAK-inhibitors, lessons from the UK on vaccination, mixing vaccines for prime and boost doses (PDF 162 KB)
- 17 May 2021 - Mental health, Pfizer and AstraZeneca vaccine effectiveness in older adults, NHS England tackles surgical backlog (PDF 140 KB)
- 14 May 2021 - Written information to address vaccine hesitancy, complexity of COVID-19 vaccine patents, assessing physician resilience (PDF 151 KB)
- 13 May 2021 - Telehealth use in EDs, quality improvement during COVID-19, strategies to address vaccine hesitancy (PDF 145 KB)
- 12 May 2021 - COVID-19 and lung cancer, self-testing, precision medicine for COVID-19 (PDF 135 KB)
- 11 May 2021 - Vaccination strategies and herd immunity, drug treatments for COVID-19, SARS-CoV-2 transmission Q&A (PDF 152 KB)
- 10 May 2021 - Paediatric COVID-19, effective COVID-19 vaccine communication, aerosol generating procedures and transmission, infections post-Pfizer vaccination (PDF 176 KB)
- 7 May 2021 - Respiratory outcomes 3, 6 and 12 months post COVID-19 hospitalisation, Pfizer vaccination in Israel, vaccines in solid organ transplant recipients (PDF 148 KB)
- 6 May 2021 - UK guidance on preventing SARS-CoV-2 transmission, testing at scale, the SARS-CoV-2 ‘viral arms race’ (PDF 194 KB)
- 5 May 2021 - Digital contact tracing, T-cell count as a prognostic marker, social distancing and airborne transmission, vaccine hesitancy (PDF 129 KB)
- 4 May 2021 - Tocilizumab in hospital patients, recovery strategies for cervical screening, a potential COVID-19 baby boom in Australia (PDF 201 KB)
- 3 May 2021 - The OxCOVID global database, BMI and COVID-19 severity, pulmonary fibrosis four months after severe COVID-19, the first billion vaccine doses (PDF 183 KB)
- 30 Apr 2021 - Pfizer vaccine in people with cancer, app for tracking post-vaccination side effects, vaccination and household transmission (PDF 175 KB)
- 29 Apr 2021 - COVID-19 related pressure injuries in patients and personnel, vaccine efficacy, social deprivation and mortality (PDF 142 KB)
- 28 Apr 2021 - Prophylaxis against COVID-19, immune-related manifestations of COVID-19, silent COVID-19 infections in children (PDF 153 KB)
- 27 Apr 2021 - COVID-19 risk with nebulisers, fewer hospitalisations and community cases in the UK, variant under investigation B.1.617 (India) (PDF 153 KB)
- 26 Apr 2021 - Stroke and SARS-CoV-2, post-acute sequelae of COVID-19 characterised, maternal and neonatal morbidity and mortality (PDF 152 KB)
- 23 Apr 2021 - Johnson & Johnson vaccine phase 3 trial, vaccine breakthrough infections with SARS-CoV-2 variants, India’s COVID-19 surge (PDF 188 KB)
- 22 Apr 2021 - Geographic differences in COVID-19 comorbidities, post-mortem after vaccination, COVID-19 in clinicians (PDF 151 KB)
- 21 Apr 2021 - Cardiac abnormalities in COVID-19 patients, monoclonal antibodies, the P1 (Brazil) variant and increased mortality in young people (PDF 148 KB)
- 20 Apr 2021 - COVID-19-funded research projects, reuse of N95 respirators, COVID-19 detection from breath and cough audio signals (PDF 174 KB)
- 19 Apr 2021 - Thoracic imaging for diagnosis, variants and vaccine efficacy, asymptomatic cases despite vaccination (PDF 141 KB)
- 16 Apr 2021 - Viral shedding and transmission, thrombotic thrombocytopaenia after vaccination (PDF 160 KB)
- 15 Apr 2021 - Interferon therapy, anticoagulation in COVID-19, autoimmune disease and post-acute COVID-19 syndrome (PDF 175 KB)
- 14 Apr 2021 - Contact tracing technologies, antibody response to Pfizer vaccine in dialysis patients, gut microbiota and COVID-19 (PDF 164 KB)
- 13 Apr 2021 - Budesonide as a treatment for early COVID-19, cutaneous reactions to vaccines, medico-legal aspects of telehealth encounters (PDF 224 KB)
- 12 Apr 2021 - Post-vaccine thrombosis, drug treatments for COVID-19, vaccine passports (PDF 176 KB)
- 1 Apr 2021 - COVID-19 and obesity, cholesterol and triglyceride levels and severity, country-level risk and response to COVID-19 (PDF 142 KB)
- 31 Mar 2021 - Reduced viral load post-Pfizer vaccine, SARS-CoV-2 infection and radiation therapy, US COVID-19 cases rise while vaccinations increase (PDF 162 KB)
- 30 Mar 2021 - The effect of COVID-19 on the brain, mask use, the Critical Health Resources Information System (CHRIS) in Australia’s intensive care units (PDF 227 KB)
- 29 Mar 2021 - Vaccine hesitancy in Australia, COVID-19 and population ageing, risk-based mammography (PDF 154 KB)
- 26 Mar 2021 - Asymptomatic COVID-19, vaccines in immunosuppressed patients, dynamics of antibody responses, communities of practice (PDF 157 KB)
- 25 Mar 2021 - Transmission in critical care, influenza and SARS-CoV-2 infectivity, routine testing strategies for airline travel (PDF 159 KB)
- 24 Mar 2021 - Post-acute sequelae of COVID-19 (PASC), new digital models of care in ophthalmology, key steps in the Australian vaccine program (PDF 169 KB)
- 23 Mar 2021 - Neutralising antibodies after infection and vaccination, living with children and the risk of COVID-19, vaccine second-dose completion in the US (PDF 156 KB)
- 22 Mar 2021 - Durability of neutralising antibodies, malnutrition risk with CPAP, has COVID-19 peaked? (PDF 154 KB)
- 19 Mar 2021 - AstraZeneca vaccine efficacy against B.1.351 (South Africa) variant, ED presentations from Sydney quarantine hotels, reinfection rates (PDF 176 KB)
- 18 Mar 2021 - COVID-19 and stroke services in Australia, COVID-19 and artificial intelligence, Rehabilitation Research Framework for COVID-19 patients (PDF 167 KB)
- 17 Mar 2021 - Mortality and the UK / Kent variant, a ‘Green Pass’ post-vaccination proposal in Israel, timeline of immunological insights about COVID-19 (PDF 176 KB)
- 16 Mar 2021 - Serial interval and incubation period, surgery following COVID-19 infection, the impact of the vaccination program in Israel (PDF 205 KB)
- 15 Mar 2021 - Quality of COVID-19 clinical guidelines, phase 1 trial of Johnson & Johnson vaccine, COVID-19 and seasonal influenza comparisons (PDF 175 KB)
- 12 Mar 2021 - Heightened risk of mortality with the UK/Kent variant, COVID-19 and liver disease, virtual health care for community management in Australia (PDF 143 KB)
- 11 Mar 2021 - Phase 2 trial of Covaxin, serosurveys for public health decision-making, Pfizer vaccine effectiveness (PDF 175 KB)
- 10 Mar 2021 - GP experience of COVID-19 in Australia, risks of delaying second vaccine dose, COVID-19 symptom persistence for up to 10 months (PDF 141 KB)
- 9 Mar 2021 - Different country responses to COVID-19, digital inequities in supporting young indigenous Australians (PDF 176 KB)
- 8 Mar 2021 - Mobile robotics for patient evaluation, SARS-CoV-2 on ocular surfaces, antivaccination infodemic, optimal use of different vaccines (PDF 156 KB)
- 5 Mar 2021 - Reprocessing N95 respirators, satisfaction with telehealth, approaches to promote adherence to physical distancing. (PDF 181 KB)
- 4 Mar 2021 - Incubation period, lateral flow assays, effectiveness of Pfizer and AstraZeneca vaccines in England (PDF 153 KB)
- 3 Mar 2021 - Mutation D614G and enhanced transmission, patients with cancer and COVID-19, the Johnson & Johnson vaccine, phase 2 trial of Novavax (PDF 171 KB)
- 2 Mar 2021 - Obesity and vaccine efficacy, backward contact tracing, indirect impacts of COVID-19 on Aboriginal communities (PDF 186 KB)
- 1 Mar 2021 - Psychological illness after COVID-19, the RECOVERY platform’s dexamethasone trial, effectiveness of Pfizer vaccine (PDF 201 KB)
- 26 Feb 2021 - The downsides of face masks, seropositivity and future infection risk, immune escape of variants (PDF 154 KB)
- 25 Feb 2021 - Arterial and venous thromboembolism, a multiple site outbreak in Sydney, spread and dominance of B.1.1.7 (UK / Kent) variant across Europe (PDF 164 KB)
- 24 Feb 2021 - Moderna vaccine and the South African variant of concern, uncertainty in modelling, insights from behavioural economics (PDF 146 KB)
- 23 Feb 2021 - AstraZeneca single dose efficacy at 90 days, rate reduction in SARS-CoV-2 infection and COVID-19 post Pfizer vaccination, super-spreaders (PDF 195 KB)
- 22 Feb 2021 - Years of life lost to COVID-19, payments for vaccination, news media and risk narratives, vaccine ‘real world’ effectiveness (PDF 184 KB)
- 19 Feb 2021 - Convalescent plasma therapy, vitamin D3 treatment, neutralising activity of Moderna and Pfizer vaccines against variants of concern (PDF 156 KB)
- 18 Feb 2021 - Paediatric COVID-19, vaccine side effects, a potential endemic future (PDF 134 KB)
- 17 Feb 2021 - Diagnostic tests, variants, effectiveness of Pfizer vaccine, a decision framework to guide social and movement measures (PDF 168 KB)
- 16 Feb 2021 - Zinc and ascorbic acid supplements do not affect symptoms, prophylactic anticoagulation, single dose of Pfizer vaccine in Israel (PDF 158 KB)
- 15 Feb 2021 - Face mask efficacy, COVID-19 detection by dogs, the pandemic’s first year (PDF 174 KB)
- 12 Feb 2021 - SARS-CoV-2 genome and antibodies in breastmilk, transmission rates in specific settings, Moderna and Pfizer vaccine efficacy against variants (PDF 138 KB)
- 11 Feb 2021 - Asymptomatic SARS-CoV-2 carriers, update on remdesivir, Pfizer vaccine response in recovered COVID-19 patients. (PDF 153 KB)
- 10 Feb 2021 - Prevention of SARS-CoV-2 transmission in hospital air, preoperative assessment decisions, viral load post-vaccination (PDF 144 KB)
- 9 Feb 2021 - PPE and healthcare workers, COVID-19 incubation period, multiple studies on vaccines and variants of concern (PDF 163 KB)
- 8 Feb 2021 - Statin use, phase 1/2 trial for CoronaVac, nasopharyngeal decolonisation (PDF 156 KB)
- 5 Feb 2021 - Prediction models for diagnosis and prognosis, the RECOVERY trial and azithromycin, rapid testing technologies (PDF 148 KB)
- 4 Feb 2021 - Sputnik vaccine phase 3 trial, mortality in intensive care, SARS-CoV-2 persistence post-recovery (PDF 147 KB)
- 3 Feb 2021 - Post-vaccination COVID-19 symptoms in Israel, antibody responses to single dose vaccination in previously infected people (PDF 139 KB)
- 2 Feb 2021 - Face masks in the community, COVID-19 recurrence, point-of-care testing (PDF 189 KB)
- 1 Feb 2021 - Demand and occupancy in Australian EDs during the pandemic, social distancing and vaccinations, Novavax phase 3 trials (PDF 123 KB)
- 29 Jan 2021 - Pfizer vaccine neutralisation of new variants, ivermectin, effective communication strategies (PDF 132 KB)
- 28 Jan 2021 - Vaccines for patients with IBD, diabetes and for pregnant women, future epidemiology and clinical trial research, early data on UK vaccine rollout (PDF 146 KB)
- 27 Jan 2021 - Asymptomatic infections, guidelines for long term effects of COVID-19, global preparedness and pandemic warning systems (PDF 142 KB)
- 25 Jan 2021 - Vaccine prioritisation and commentary, monoclonal antibodies (-mabs), non-pharmaceutical interventions (PDF 151 KB)
- 22 Jan 2021 - New evidence on variants, remote vital sign monitoring, COVID-19 deniers (PDF 135 KB)
- 21 Jan 2021 - Pandemic rostering in Victorian EDs, COVID-19 reinfection, UK guidance on vaccines for patients on anti-cancer therapy (PDF 137 KB)
- 20 Jan 2021 - Vaccines and allergies, antibody responses, in-flight transmission of SARS-CoV-2, COVID-19 guidance for Aboriginal people (PDF 143 KB)
- 19 Jan 2021 - Saliva versus nasopharyngeal swabs, vaccine schedule and adverse events, post-acute COVID-19 (PDF 234 KB)
- 14 Jan 2021 - Vaccines (PDF 206 KB)
- 18 Dec 2020 - Cancer surgery delays, pulmonary embolism and DVT, Guillain Barré Syndrome, COVID-19 mortality in US adults (PDF 162 KB)
- 17 Dec 2020 - Household transmission, government interventions, vaccine promotion (PDF 138 KB)
- 16 Dec 2020 - Allocation of mechanical ventilators, gene editing, fever monitoring using wearables, vaccine approvals (PDF 133 KB)
- 15 Dec 2020 - False-negative COVID-19 tests, vaccine trials, artificial intelligence, framework for surge planning (PDF 151 KB)
- 14 Dec 2020 - Primary care responses to COVID-19, SARS-CoV-2-specific immune memory, equitable access to vaccines, mass screening programs (PDF 154 KB)
- 11 Dec 2020 - Age-specific COVID-19 fatality rates, emergency use designation for vaccines, ethics of “safer infection sites” (PDF 175 KB)
- 10 Dec 2020 - Oxford-AstraZeneca vaccine, face masks and social distancing, rapid and mass testing (PDF 147 KB)
- 9 Dec 2020 - Mental health and lockdown, integrated care for long COVID, experience of a vaccine trial, OECD and NHS guidance (PDF 135 KB)
- 8 Dec 2020 - Healthcare worker mortality, paediatric perforated appendicitis, mortality risk prediction using vital signs, iatrogenic skull base injury (PDF 137 KB)
- 7 Dec 2020 - Reopening schools, telehealth implementation, health consequences of COVID-19, intended vaccine uptake (PDF 141 KB)
- 4 Dec 2020 - Long-distance droplet transmission, COVID-19 data sharing, vaccines (PDF 133 KB)
- 3 Dec 2020 - Pre-existing mental illness and pandemics, rehabilitation for critically ill patients with COVID-19, WHO guidance on mask use (PDF 115 KB)
- 2 Dec 2020 - Outdoor transmission of SARS-CoV-2, UK vaccination strategy, patents and COVID-19 vaccines (PDF 131 KB)
- 1 Dec 2020 - Impact of COVID-19 on cancer survivors, respirator reuse, international alcohol consumption, influenza in Australia (PDF 165 KB)
- 30 Nov 2020 - Recurrent positivity, impact on cornea donation, vaccine cost effectiveness (PDF 142 KB)
- 27 Nov 2020 - Convalescent plasma, database on government responses to COVID-19, science communication (PDF 180 KB)
- 26 Nov 2020 - Economic evaluation, surface contamination, SARS-CoV-2 reinfection (PDF 133 KB)
- 25 Nov 2020 - COVID-19 emergency and palliative care, the NSW Critical Intelligence Unit, vaccine allocation (PDF 133 KB)
- 24 Nov 2020 - Surgical practice, effects of intravenous immunoglobulin, body mass index (BMI) and COVID-19, vaccine implementation (PDF 165 KB)
- 23 Nov 2020 - Preparing for resurgence, antibiotic use in COVID-19, mass screening, behavioural insights (PDF 138 KB)
- 20 Nov 2020 - Mask effectiveness, pre-symptomatic detection using smartwatch data (PDF 136 KB)
- 19 Nov 2020 - Management of obstetric emergencies, suicide in Queensland, immune suppression, acute pancreatitis (PDF 140 KB)
- 18 Nov 2020 - Effectiveness of non-pharmaceutical interventions, maternal mental health, COVID-19 testing in the UK (PDF 140 KB)
- 17 Nov 2020 - Randomised trials, politicisation of science, superspreading (PDF 192 KB)
- 16 Nov 2020 - Reproductive number (R0), low dose far-UVC lighting, collider bias, suicide trends (PDF 138 KB)
- 13 Nov 2020 - Sampling methods, Sydney seroprevalence, airborne dispersal in hospitals (PDF 155 KB)
- 12 Nov 2020 - COVID-19 and psychiatric disorder, neonatal COVID-19, seven critical lessons, mink farms (PDF 131 KB)
- 11 Nov 2020 - Real-time localised risk information, human challenge studies, Pfizer vaccine (PDF 132 KB)
- 10 Nov 2020 - Surgical masks versus respirators, household transmission, bus contamination (PDF 139 KB)
- 9 Nov 2020 - COVID-19 tests, remdesivir, impact on notifiable diseases (PDF 135 KB)
- 6 Nov 2020 - Draping in surgical procedures, chatbots for COVID-19 screening, cardiac rehabilitation, supporting resilience in frontline staff (PDF 168 KB)
- 5 Nov 2020 - Recurrence of COVID-19, venous thromboembolism, fatality rates across countries, WHO insights (PDF 159 KB)
- 4 Nov 2020 - Gastrointestinal and liver injury, elective surgery, mortality and immunity patterns, science denial and conspiracy theories (PDF 139 KB)
- 3 Nov 2020 - Out of hospital cardiac arrest, organotropism, neurological and rheumatic manifestions, near-source wastewater tracking (PDF 171 KB)
- 2 Nov 2020 - Vaccine efficacy, case vignettes, super-spreaders and super-susceptibles (PDF 138 KB)
- 30 Oct 2020 - Ischaemic stroke, neutralising antibodies, second wave, vaccines (PDF 158 KB)
- 29 Oct 2020 - Airborne transmission, PPE in the Emergency Department, frailty (PDF 142 KB)
- 28 Oct 2020 - Transmission, deferred care, gestational diabetes, junior doctors (PDF 160 KB)
- 27 Oct 2020 - Convalescent plasma ineffective, ventilation management, decreases in organ donation as an indirect impact (PDF 141 KB)
- 26 Oct 2020 - Lifting non-pharmaceutical interventions, vaccines, engines of spread, incubation period (PDF 167 KB)
- 23 Oct 2020 - Child and family outcomes post-pandemics, ICU contamination, epidemic suppression and vaccine development (PDF 166 KB)
- 23 Oct 2020 - Neurological manifestations, postoperative mortality, congregate living settings, viral shedding (PDF 147 KB)
- 21 Oct 2020 - Acknowledging uncertainty, scientific divisions, herd immunity, ultraviolet-B radiation, vaccines (PDF 134 KB)
- 20 Oct 2020 - Cytokine elevation, virtual cancer genetic services, comparative evidence on drug treatments, immunity passports (PDF 140 KB)
- 19 Oct 2020 - Re-positive patients, sensible medicine, COVID-19 ‘circuit breaks’ (PDF 171 KB)
- 16 Oct 2020 - All-cause mortality, orthopaedic trauma at RNSH, COVID-19 vaccines (PDF 140 KB)
- 15 Oct 2020 - Takotsubo syndrome, arrhythmias in COVID-19, reinfection (PDF 137 KB)
- 14 Oct 2020 - Aerosol-generating procedures, vertical transmission during pregnancy, pandemic staffing, excess deaths (PDF 145 KB)
- 13 Oct 2020 - Cutaneous COVID-19, regional strategies, complexity science, post-traumatic growth (PDF 163 KB)
- 12 Oct 2020 - Psychological impact of isolation, portable negative pressure innovation, sewage surveillance (PDF 147 KB)
- 9 Oct 2020 - Aerosols and extubation, severe paediatric ketoacidosis, public health research needs (PDF 172 KB)
- 8 Oct 2020 - Acute kidney injury, super-spreaders, communicating risk (PDF 144 KB)
- 7 Oct 2020 - Prophylactic anticoagulants, in-hospital cardiac arrest, changes in alcohol consumption, social license and big data (PDF 166 KB)
- 2 Oct 2020 - Research letters on aortic valve replacement, in-hospital cardiac arrests, older people in vaccine trials (PDF 169 KB)
- 1 Oct 2020 - Hand sanitisers, stroke, flight-associated transmission, off-label use of disinfectants (PDF 139 KB)
- 30 Sep 2020 - Ventilation, general practice, health system preparedness, social distancing and border restrictions (PDF 123 KB)
- 29 Sep 2020 - E-mental health solutions, Favipiravir, poor appetite and overeating during COVID-19, ethics of health worker wellbeing (PDF 142 KB)
- 28 Sep 2020 - Easing restrictions, efficacy of masks, patient heterogeneity, herd immunity, telerehabilitation (PDF 138 KB)
- 25 Sep 2020 - Pulmonary embolism, politicisation of mask use, animal models for testing, TGA regulation of PPE (PDF 361 KB)
- 24 Sep 2020 - ECMO telerounding, point-of-care tests, digital health (PDF 216 KB)
- 23 Sep 2020 - Cocooning vulnerable populations, cancer care in Victoria, community testing, decreased ED wait times (PDF 216 KB)
- 22 Sep 2020 - Temperature and humidity, methylprednisolone, in-flight transmission, viral loads (PDF 224 KB)
- 21 Sep 2020 - COVID-19 transmission, antiviral therapeutics, intimate partner violence, pre-existing immunity, clusters and super-spreading (PDF 217 KB)
- 18 Sep 2020 - Diabetes, cultural norms, voice assistants, vaccine update (PDF 468 KB)
- 17 Sep 2020 - Universal screening, guideline development, intention to vaccinate (PDF 314 KB)
- 16 Sep 2020 - Effect of quarantine and social restrictions, duration of COVID-19 immunity, targeted testing (PDF 564 KB)
- 15 Sep 2020 - Drug treatments, adaptive immunity, influenza and COVID-19, speech-generated transmission (PDF 190 KB)
- 14 Sep 2020 - Alternative service delivery, risk communication, vaccine confidence, outdoor transmission (PDF 369 KB)
- 11 Sep 2020 - Trauma admissions in Westmead Hospital, innate immunity, herd immunity, vaccines (PDF 220 KB)
- 10 Sep 2020 - Antibody testing, reduced C.difficile infections, equitable access to vaccines, “variolation” (PDF 296 KB)
- 9 Sep 2020 - COVID-19 indirect impact, role of centres of government, non-communicable diseases (PDF 215 KB)
- 8 Sep 2020 - Modelling transmission in Victoria, visual summary of drug treatments, corticosteroids, vaccines, healthcare simulation models (PDF 225 KB)
- 7 Sep 2020 - Systemic corticosteroids, non-communicable diseases, asymptomatic transmission (PDF 352 KB)
- 4 Sep 2020 - Maternal and perinatal outcomes, contact tracing, oxygen targets for mechanical ventilation (PDF 338 KB)
- 3 Sep 2020 - Viral transmission, equity, managing uncertainty, mobility data (PDF 368 KB)
- 2 Sep 2020 - Medical education, localised lockdowns, long-term care services (PDF 179 KB)
- 1 Sep 2020 - Oxygen therapy and infection risk, triage, immune response (PDF 368 KB)
- 31 Aug 2020 - Post-pandemic clinician mental health, air travel, international data descriptors, mask use, transmission in schools (PDF 228 KB)
- 28 Aug 2020 - High flow nasal cannula, diabetes, COVID-19 reinfection, physical distancing, data visualisation (PDF 559 KB)
- 27 Aug 2020 - Psychological morbidities, lung transplantation, machine learning, COVID-19 heroes (PDF 322 KB)
- 26 Aug 2020 - Haematological and immunological markers, vulnerable populations, aerosol transmission, home care guidelines (PDF 322 KB)
- 25 Aug 2020 - Disease management, clinical trials, enhancing value post-COVID-19, fit checking masks (PDF 366 KB)
- 24 Aug 2020 - Powered air purifying respirators (PAPR), serological testing, psychiatric syndromes (PDF 319 KB)
- 21 Aug 2020 - Testing strategies, mental health, fast‐track care for diabetic foot ulcers (PDF 335 KB)
- 20 Aug 2020 - Radiation fractionation, telemedicine in cardiovascular surgery, Auxora randomised controlled trial, advance care planning (PDF 423 KB)
- 19 Aug 2020 - Mental health, pulmonary cavitation, long-term care facilities (PDF 465 KB)
- 18 Aug 2020 - Endoscopy services, teledentistry, drug repurposing (PDF 365 KB)
- 17 Aug 2020 - Risk factors, ECMO, haemodynamic monitoring, diabetes (PDF 435 KB)
- 14 Aug 2020 - Convalescent plasma, obesity, precision public health (PDF 472 KB)
- 13 Aug 2020 - Tracking the spread, digital public health, post-acute COVID-19, telmisartan (PDF 373 KB)
- 12 Aug 2020 - Antiviral agents, telehealth, palliative care, translated COVID-19 resources (PDF 188 KB)
- 11 Aug 2020 - Health economics and trade-offs, variation in management of severe COVID-19, WHO indicators (PDF 371 KB)
- 10 Aug 2020 - Children and COVID-19, recovery from severe disease, responses to domestic violence, elimination strategies (PDF 576 KB)
- 7 Aug 2020 - Immunotherapies, medical waste, healthcare worker wellbeing (PDF 360 KB)
- 6 Aug 2020 - ECMO, reopening schools, healthcare workers, WHO timeline (PDF 227 KB)
- 5 Aug 2020 - Cancer immunotherapy, oral health services and long-term respiratory complications (PDF 313 KB)
- 4 Aug 2020 - Vaccine evaluation, living review of drug treatments, rehabilitation, cellular immune response, modelling hospital resource needs (PDF 475 KB)
- 3 Aug 2020 - Thrombolysis for STEMI, Proton Pump Inhibitors, PCR positivity in healthcare workers (PDF 360 KB)
- 31 Jul 2020 - School closures, reflections from American CEOs, wastewater surveillance (PDF 424 KB)
- 30 Jul 2020 - Stroke and preceding infection, behavioural science, travel restrictions (PDF 337 KB)
- 29 Jul 2020 - Aboriginal people at risk, pregnancy, planned care (PDF 324 KB)
- 28 Jul 2020 - Coagulopathy, aerosols, contact tracing, mental health (PDF 437 KB)
- 27 Jul 2020 - Peer reviewed journals featured (PDF 298 KB)
- 24 Jul 2020 - Health system and quality perspectives, vulnerable populations (PDF 441 KB)
- 23 Jul 2020 - Impact of delays in cancer referral and diagnosis, national preparedness, tailoring contact, treatment and support for ethnic groups (PDF 191 KB)
- 22 Jul 2020 - Vaccine trials, patient-reported data, emergency preparedness (PDF 315 KB)
- 21 Jul 2020 - Risk tool, Victoria lockdown, disease recurrence, defining COVID-19 deaths (PDF 475 KB)
- 20 Jul 2020 - Physical distancing, contact tracing, inequalities, screening and risk (PDF 617 KB)
- 17 Jul 2020 - Diagnostic tests, impacts on healthcare workers, resuming elective surgery (PDF 481 KB)
- 16 Jul 2020 - Viral transmission, vaccine development, probiotics, leadership,triage (PDF 344 KB)
- 15 Jul 2020 - Acute kidney injury, convalescent plasma, College updates (PDF 422 KB)
- 14 Jul 2020 - Extra‐pulmonary symptoms, gendered attitudes, persistence of antibodies (PDF 440 KB)
- 13 Jul 2020 - Surgical workflow, infection prevention precautions and global health law (PDF 416 KB)
- 10 Jul 2020 - Reshaping Australia’s health system, RECOVERY trial and rehabilitation post COVID-19 (PDF 312 KB)
- 9 Jul 2020 - Comparative clinical studies, cancer care, and disparities (PDF 290 KB)
- 8 Jul 2020 - Lung abnormalities, immunology, cardiac tele-rehabilitation (PDF 174 KB)
- 7 Jul 2020 - Digital pathology, fomites, health literacy, mobile-health (PDF 227 KB)
- 6 Jul 2020 - Serological tests, excess deaths, cancer care and surgical recovery (PDF 224 KB)
- 3 Jul 2020 - Frailty, intensive care, social distancing, and telehealth. (PDF 324 KB)
- 2 Jul 2020 - Global perspectives, PPE training, stroke, podcasts (PDF 519 KB)
- 1 Jul 2020 - Loneliness, risk communication, screening pre-surgery (PDF 181 KB)
- 30 Jun 2020 - Infection control, high flow nasal cannulae, Twitter, influenza (PDF 388 KB)
- 27 Jun 2020 - Antibody tests, PPE, resuscitation, surveillance (PDF 493 KB)
- 26 Jun 2020 - Healthcare reform, lessons and innovations and research priorities (PDF 481 KB)
- 25 Jun 2020 - Telehealth, comorbidities, depression and anxiety (PDF 477 KB)
- 24 Jun 2020 - Evidence synthesis, pathology findings, and transmission (PDF 223 KB)
- 23 Jun 2020 - Artificial intelligence, masks, ethical dilemmas and exist strategies (PDF 310 KB)
- 20 Jun 2020 - Home pulse oximetry, transmission dynamics, and virtual hospitals (PDF 435 KB)
- 19 Jun 2020 - Genome, telemedicine, ethics, dexamethasone trial (PDF 443 KB)
- 18 Jun 2020 - Environmental contamination, vaccinations during COVID-19, research (PDF 339 KB)
- 17 Jun 2020 - Urology, diabetes, rheumatic disease, stroke, occupational health (PDF 427 KB)
- 16 Jun 2020 - Ethics, viral transmission, equity and ‘lockdown’ (PDF 394 KB)
- 13 Jun 2020 - Telehealth, maternal complications and extra-pulmonary presentations (PDF 179 KB)
- 12 Jun 2020 - Mental health, drug repositioning, phone apps and homelessness (PDF 434 KB)
- 11 Jun 2020 - Antivirals, long-term intubation, bacterial co-infection (PDF 200 KB)
- 10 Jun 2020 - Testing, diabetes, ethics of drug repurposing, Google search trends, extended use and reuse of facemasks (PDF 337 KB)
- 6 Jun 2020 - Non-invasive and extracorporeal oxygenation, mask reuse, adapting care (PDF 437 KB)
- 5 Jun 2020 - Aerosol generating procedures, challenges for EDs, myocardial injury (PDF 442 KB)
- 4 Jun 2020 - Physical distancing, face masks, heart failure, research quality (PDF 444 KB)
- 3 Jun 2020 - Hypertension, mental health, staff wellness, system responses (PDF 227 KB)
- 2 Jun 2020 - Cancer, clinical trials, telehealth, and managing teamwork (PDF 487 KB)
- 30 May 2020 - Stroke, ‘outbreak rostering’, viewpoints on policy and clinical research (PDF 286 KB)
- 29 May 2020 - Cardiac imaging, frailty, 3D printed swabs and rural emergency care toolkit (PDF 186 KB)
- 28 May 2020 - Ventilation techniques, medical education, neurosurgery, smoking and nicotine (PDF 324 KB)
- 27 May 2020 - Cardiovascular disease, risk factors, and convalescent plasma (PDF 309 KB)
- 26 May 2020 - Peer reviewed journals (PDF 384 KB)
- 23 May 2020 - Nutrition, conspiracy theories, supply chain management, cancer care (PDF 202 KB)
- 22 May 2020 - Clinical course, thrombotic risk, evidence-based virtual care (PDF 425 KB)
- 21 May 2020 - Non-COVID ED presentations, disability rights, virtual care in NICU and obstetrics, cancer (PDF 333 KB)
- 20 May 2020 - Safety of corticosteroids, infection control measures, climate and mortality risk (PDF 190 KB)
- 19 May 2020 - ICU modelling, nutritional risk, spinal cord injury, diabetes (PDF 380 KB)
- 16 May 2020 - Call for robust trials, convalescent plasma, screening, mortality (PDF 321 KB)
- 15 May 2020 - Multi-organ involvement, transmission, simulations, and operating rooms (PDF 443 KB)
- 14 May 2020 - Steroids, triage algorithm, ventilator allocation, prognostic tool (PDF 476 KB)
- 13 May 2020 - Research informed strategy, equity, post infection immunity, symptom tracking (PDF 234 KB)
- 12 May 2020 - Triple combination treatment, NSW response, non-communicable disease (PDF 315 KB)
- 9 May 2020 - Screening and diagnosis, paediatrics, post-COVID strategies (PDF 201 KB)
- 8 May 2020 - Anticoagulation, community-based healthcare, and acute kidney injury (PDF 349 KB)
- 7 May 2020 - International lessons, emergency departments, acute stroke management (PDF 348 KB)
- 6 May 2020 - Telemedicine, ethics, equity and NATSIHWA collaboration toolkit (PDF 254 KB)
- 5 May 2020 - Drug treatments, restarting surgeries, and populations-in-focus (PDF 456 KB)
- 2 May 2020 - Myocardial injury, obesity, second waves, patient voice (PDF 322 KB)
- 1 May 2020 - First Nations people, immunosuppressive therapies, stroke, remdesivir (PDF 642 KB)
- 30 Apr 2020 - Protective immunity, immunosuppressed patients, pathophysiology (PDF 325 KB)
- 29 Apr 2020 - Pregnancy, policy comparisons, influenza during COVID-19 (PDF 188 KB)
- 28 Apr 2020 - Diabetes, kidney transplants, opioid dependence, COVIDSafe (PDF 330 KB)
- 25 Apr 2020 - Screening healthcare workers, nutrition and food safety, webinars (PDF 196 KB)
- 24 Apr 2020 - Modelling, epidemiology, suicide risk, preventing hospital admissions (PDF 595 KB)
- 23 Apr 2020 - Endotheliitis, ventilator demand, testing, infection control, the path forward (PDF 189 KB)
- 22 Apr 2020 - Views from oncologists, masks, wellbeing, exit strategies (PDF 431 KB)
- 21 Apr 2020 - Testing, oncology, health system responses, resuming elective surgery (PDF 386 KB)
- 18 Apr 2020 - Cohort study, telehealth, oxygen therapy, protective gowns, WHO guidance (PDF 494 KB)
- 17 Apr 2020 - PPE, updates from WHO, health messaging for Aboriginal communities (PDF 460 KB)
- 16 Apr 2020 - Emerging from lockdown, testing, treatments, and nosocomial infection (PDF 416 KB)
- 15 Apr 2020 - Respiratory and diabetes guidance, infection control and underreporting (PDF 308 KB)
- 10 Apr 2020 - Second-wave transmission, managing diabetes, pain (PDF 327 KB)
- 9 Apr 2020 - Diagnostic testing, addressing ICU challenges, correctional facilities (PDF 270 KB)
- 8 Apr 2020 - Virology, temporary hospitals, reorganisation of care, leadership (PDF 249 KB)
- 7 Apr 2020 - ACE-I/ARB continued use, CVD advice, burns, diabetes (PDF 253 KB)
- 4 Apr 2020 - NICE guidelines, mental health, telehealth, ethics (PDF 260 KB)
- 3 Apr 2020 - New guidance on emergency medicine, re-use of face-piece respirators, NSAIDs, podcasts, tiered staffing (PDF 594 KB)
- 2 Apr 2020 - New guidance for Aboriginal people, GP telehealth, surge capacity, model-based analysis of severity, vulnerable workforce (PDF 282 KB)
- 1 Apr 2020 - CPAP, neurosurgery, occupational medicine, surgery, gastroenterology, maintaining essential services, spirometry (PDF 403 KB)
- 31 Mar 2020 - New guidance, cardiac patients, rapid EBM reviews, ED, telehealth (PDF 442 KB)
- 27 Mar 2020 - Community health workers, elective surgery, hospital capacity, telehealth, de-isolation, modelling, clinical trials (PDF 480 KB)
- 26 Mar 2020 - Ethics, remote assessment, use of mechanical ventilation in UK, management strategies in China (PDF 274 KB)
The daily evidence digest collates recently released reports and evidence – provision of this information and weblinks does not imply endorsement nor recommendation.